Shares of Aura Biosciences, Inc. (NASDAQ:AURA – Get Free Report) have earned an average rating of “Buy” from the seven ratings firms that are presently covering the stock, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $23.00.
Several analysts have issued reports on the company. Cowen restated a “buy” rating on shares of Aura Biosciences in a research note on Friday, October 18th. Evercore ISI upgraded shares of Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 16th. Lifesci Capital upgraded Aura Biosciences to a “strong-buy” rating in a report on Monday, September 9th. JMP Securities increased their target price on Aura Biosciences from $19.00 to $23.00 and gave the stock a “market outperform” rating in a research note on Friday, September 13th. Finally, HC Wainwright restated a “buy” rating and issued a $22.00 price target on shares of Aura Biosciences in a research note on Thursday, November 14th.
Get Our Latest Analysis on AURA
Aura Biosciences Trading Down 0.4 %
Aura Biosciences (NASDAQ:AURA – Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.02. As a group, research analysts forecast that Aura Biosciences will post -1.66 earnings per share for the current year.
Insider Activity at Aura Biosciences
In other Aura Biosciences news, CTO Mark Plavsic sold 7,383 shares of the business’s stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $9.85, for a total transaction of $72,722.55. Following the sale, the chief technology officer now directly owns 121,132 shares of the company’s stock, valued at $1,193,150.20. The trade was a 5.74 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Julie B. Feder sold 25,131 shares of the firm’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $12.03, for a total transaction of $302,325.93. Following the transaction, the chief financial officer now directly owns 134,276 shares of the company’s stock, valued at $1,615,340.28. The trade was a 15.77 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 79,081 shares of company stock valued at $891,353 in the last 90 days. 5.40% of the stock is owned by corporate insiders.
Institutional Trading of Aura Biosciences
A number of institutional investors and hedge funds have recently bought and sold shares of AURA. American Century Companies Inc. acquired a new position in shares of Aura Biosciences in the second quarter worth approximately $119,000. SG Americas Securities LLC acquired a new position in shares of Aura Biosciences in the 3rd quarter worth approximately $169,000. Rhumbline Advisers increased its position in shares of Aura Biosciences by 39.6% during the second quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock worth $480,000 after buying an additional 18,011 shares during the period. The Manufacturers Life Insurance Company raised its stake in Aura Biosciences by 14.6% during the second quarter. The Manufacturers Life Insurance Company now owns 64,452 shares of the company’s stock worth $487,000 after buying an additional 8,194 shares during the last quarter. Finally, Barclays PLC lifted its holdings in Aura Biosciences by 256.5% in the third quarter. Barclays PLC now owns 61,010 shares of the company’s stock valued at $544,000 after buying an additional 43,897 shares during the period. 96.75% of the stock is currently owned by institutional investors and hedge funds.
About Aura Biosciences
Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Featured Stories
- Five stocks we like better than Aura Biosciences
- Investing In Automotive Stocks
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- Pros And Cons Of Monthly Dividend Stocks
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- What is the Nasdaq? Complete Overview with History
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.